Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 1Phase 1/2 1

Status

Completed 5

Sponsor Class

INDUSTRY 4NIH 1

Study Type

Interventional 5

Sponsor

Cancer Type

Thoracic 5

Conditions

Breast Neoplasms 43Neoplasms 13Neoplasm Metastasis 8Sarcoma 7Carcinoma, Non-Small-Cell Lung 5Triple Negative Breast Neoplasms 4Sarcoma, Ewing 2Rhabdomyosarcoma 2Prostatic Neoplasms 2Liposarcoma 2Leiomyosarcoma 2Inflammatory Breast Neoplasms 2Carcinoma 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Salivary Gland Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Neoplasms 1Osteosarcoma 1Neoplasm, Residual 1Metastatic Urothelial Cell Cancer 1Lymphoma 1Lung Neoplasms 1Ketosis 1Histiocytoma, Malignant Fibrous 1Hemangiosarcoma 1Hemangioendothelioma, Epithelioid 1

Interventions

Carboplatin 235Pemetrexed 214Paclitaxel 160Cisplatin 150pembrolizumab 145Erlotinib Hydrochloride 141Docetaxel 133Gemcitabine 94Bevacizumab 85Nivolumab 72Radiotherapy 62atezolizumab 40Radiosurgery 37Afatinib 37osimertinib 35130-nm albumin-bound paclitaxel 35Cetuximab 34durvalumab 33Ipilimumab 32Gefitinib 31Albumin-Bound Paclitaxel 29Vinorelbine 23Taxes 22Etoposide 20Crizotinib 19Radiation 17Sorafenib 16Cyclophosphamide 16Dexamethasone 15Magnetic Resonance Spectroscopy 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Has results × Carcinoma, Non-Small-Cell Lung × eribulin × Clear all
NCT01104155 2023-06-22

Eribulin Mesylate in Combination With Intermittent Erlotinib in Patients With Previously Treated, Advanced Non-Small Cell Lung Cancer

Eisai Inc.

Phase 2 Completed
123 enrolled 11 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01126736 2023-06-22

Eribulin Mesylate Administered in Combination With Pemetrexed Versus Pemetrexed Alone as Second Line Therapy in Patients With Stage IIIB or IV Nonsquamous Non Small Cell Lung Cancer

Eisai Inc.

Phase 1/2 Completed
98 enrolled 15 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT01454934 2023-06-22

A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Treatment of Physician's Choice in Subjects With Advanced Non-Small Cell Lung Cancer

Eisai Inc.

Phase 3 Completed
540 enrolled 11 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00400829 2015-01-07

E7389 in Treating Patients With Recurrent or Progressive Stage IIIB or Stage IV Non-Small Cell Lung Cancer

National Cancer Institute (NCI)

Phase 2 Completed
66 enrolled 7 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00100932 2012-03-27

Phase II Study Of E7389, Halichondrin B Analogue, In Patients With Advanced Non-Small Cell Lung Cancer, NSCLC, Who Progressed During Or After Platinum-Based Doublet Chemotherapy

Eisai Inc.

Phase 2 Completed
106 enrolled 11 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡